DrugPatentWatch Database Preview
Details for Patent: 6,268,343
Email this page to a colleague
Which drugs does patent 6,268,343 protect, and when does it expire?
Patent 6,268,343 protects SAXENDA and VICTOZA and is included in two NDAs.
Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty-nine patent family members in twenty-three countries.
Summary for Patent: 6,268,343
| Title: | Derivatives of GLP-1 analogs |
| Abstract: | The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action. |
| Inventor(s): | Knudsen; Liselotte Bjerre (Valby, DK), Huusfeldt; Per Olaf (K.o slashed.benhavn K, DK), Nielsen; Per Franklin (V.ae butted.rl.o slashed.se, DK), Kaarsholm; Niels C. (Vanl.o slashed.se, DK), Olsen; Helle Birk (Aller.o slashed.d, DK), Bj.o slashed.rn; S.o slashed.ren Erik (Lyngby, DK), Pedersen; Freddy Zimmerdahl (V.ae butted.rl.o slashed.se, DK), Madsen; Kjeld (V.ae butted.rl.o slashed.se, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 09/258,750 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,268,343 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 6,268,343
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,268,343
International Family Members for US Patent 6,268,343
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 265224 | ⤷ Try it Free | |||
| Austria | 269103 | ⤷ Try it Free | |||
| Austria | 356830 | ⤷ Try it Free | |||
| Austria | 466026 | ⤷ Try it Free | |||
| Austria | 466027 | ⤷ Try it Free | |||
| Austria | 466028 | ⤷ Try it Free | |||
| Australia | 2610599 | ⤷ Try it Free | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
